Bedaquiline, a new antituberculosis drug, has already been used in >50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This article aims to review currently identified mechanisms of resistance and the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678, and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed. Understanding any target and non-target-based mechanisms is essential to minimize resistance development and treatment failure and help to develop appropriate DST for bedaquiline and genetic-based resistance screening.
Multidrug-resistant tuberculosis (MDR-TB) is a global health threat with high risk of morbidity and mortality, posing a challenge at the international and community level [1, 2] . MDR-TB develops by the selection of drug-resistant bacteria due to substandard treatment regimens or treatment nonadherence. In addition, drug malabsorption or drug-drug interactions leading to pharmacokinetic variability can promote the selection of drug-resistant strains [3] .
Bedaquiline inhibits the mycobacterial adenosine triphosphate (ATP) synthase [4] . It has in vitro efficacy against drug-susceptible and drug-resistant Mycobacterium tuberculosis strains [4] . Since the accelerated approval of bedaquiline for MDR-TB treatment in 2012 [5] [6] [7] [8] , >2500 patients had already received this drug in 50 countries by the end of 2015 [9] . Its use could benefit a substantial proportion of patients with MDR-TB, but hopes for improving outcomes and the large-scale use of bedaquiline are tempered by the fear of resistance rapidly emerging [10] . Reports of the emergence of bedaquiline resistance soon after introduction are alarming [9] . Therefore, there is a critical need to enable access to rapid and reliable drug susceptibility testing (DST) for all drugs, which will be used to personalize anti-TB treatment [10] . The World Health Organization (WHO) has warned that the improper use of bedaquiline could accelerate the emergence of resistance [11] . This paper aims to summarize updated information on identified mechanisms of bedaquiline resistance, review the emergence of bedaquiline resistance in clinical settings, and discuss how we might delay the accumulation and spread of acquired drug resistance to bedaquiline.
Resistance Mechanisms
Mycobacterium tuberculosis strains develop drug resistance exclusively through the selection of spontaneous chromosomal variants [12] . Inadequate or incomplete treatment can lead to the selection of resistant mutants [11] . Further treatment eradicates drug-susceptible bacteria, allowing the drug-resistant variants to become predominant [11] . If an M. tuberculosis strain is sensitive only to a single medication in a treatment regimen, the small number of bacteria randomly resistant to that medication will selectively propagate, eventually leading to treatment failure and relapse [11] . The currently known mechanisms of resistance to bedaquiline are shown in Table 1 .
The bedaquiline resistance-conferring mutations within the atpE gene were first discovered by Andries et al [4] . This gene was sequenced from in vitro-selected M. tuberculosis mutants resistant to bedaquiline, and the 2 identified point mutations (A63P and I66M) observed are both in the membrane-spanning domain region of the protein [4, 13] . These target-based mutations cause relatively high (10-128 times) increases in minimum inhibitory concentration (MIC). The resistance-associated mutations in the atpE gene appear to prevent bedaquiline from binding to the c subunit, thus maintaining H + transfer and ATP production [14] . In a larger study, gene sequencing of 53 in vitro mutants revealed 5 single point mutations (A28V, A63P, I66M, A28P, and G61A) within the atpE gene in only 15 isolates; these mutations had no detectible effect on the relative fitness in vitro [15] . No mutation within the atpE gene was observed in 72% of resistant clones, and their resistance was unexplained [15] , indicating that at least 1 additional ATP synthase-independent mechanism of bedaquiline resistance existed [15] . Moreover, no resistant mutants were isolated after exposure to 3 mg/L (the highest concentration studied) of bedaquiline, which may be the mutation-preventive concentration for M. tuberculosis [15] . Drug efflux has also been implicated in both intrinsic and acquired bedaquiline resistance [16] . When tested in the presence of efflux pump inhibitors, resistant mutants without atpE mutations had decreased bedaquiline MICs. The bedaquiline MICs of wild-type and nonresistant strains was also significantly decreased (16-fold) in the presence of verapamil [17] . Andries et al [16] investigated possible non-target-based mechanisms of acquired resistance in both preclinical and clinical M. tuberculosis strains with increased MICs for bedaquiline in vitro. Non-target-based resistance to bedaquiline was caused by mutations in Rv0678, a transcriptional repressor of the genes encoding the MmpS5-MmpL5 efflux pump. In accordance with Hartkoorn et al [18] , the MmpS5-MmpL5 mutations also caused low-level cross-resistance to clofazimine [16] . Nontarget mutations increased bedaquiline MICs increased 2-to 8-fold (0.25-0.5 mg/L) [16, 18] . Drug susceptibility evaluation by resazurine microtiter assay (REMA) clearly revealed that expression of Rv0678 (S63R) in H37Rv led to partial resistance to both clofazimine and bedaquiline [18] . Rv0678 mutants have been observed in bedaquiline-treated patients but also recently in the sputa of both MDR-TB and drug-susceptible TB patients who had received neither bedaquiline nor clofazimine treatment [19] . An MDR-TB patient who received bedaquiline on a compassionate basis for 6 months also developed bedaquiline resistance due a mutation at nucleotide position 2 (GTG → GCG) in Rv0678, resulting in the loss of the start codon N-formylmethionine to alanine). This suggests that overexpression of the mmpL5 efflux pump gene due to impaired function of the Rv0678 gene was responsible for the resistance observed. No mutations within the atpE gene were found in the relapse isolates [20] . In a recent report on acquired bedaquiline resistance, genome sequencing of 5 follow-up isolates in an MDR-TB patient who had been treated with bedaquiline revealed a mutation in Rv0678, and this mutation persisted despite bedaquiline discontinuation for >1 year [21] . Another mutation in the Rv0678 regulator gene (2 T > C leading to M1A) was also recently reported to be associated with bedaquiline and clofazimine resistance in an MDR-TB case [22] . This may indicate that atpE mutations have a cost in the patient, which is not observed in the in vitro culture. Although these mutations were observed almost entirely in patients with pre-extensively drug-resistant (XDR) and XDR-TB [16] , no clear association with poorer clinical outcome in patients administering bedaquiline combined with active companion drugs could be established [23] . Further studies are needed to determine if the moderate increase in bedaquiline MICs due to Rv0678 mutations have a negative effect on treatment response [23] . Appropriate combination therapy, adherence, and avoiding the premature discontinuation of therapy remain of critical importance [24] . Clofazimine resistance or failing on a clofazimine-containing regimen may be an additional risk for bedaquiline resistance; this should be checked before treatment initiation. To date, there is very little information on the potential determinants of drug resistance in combination regimens of clofazimine and bedaquiline; however, Rv0678 mutations should be considered [18, 25] , as a single mutation could in theory undermine the efficacy of both drugs.
Recently, the first evidence of nontarget mutations in pepQ associated with low-level resistance to clofazimine and bedaquiline in a mouse model was reported. Similar to Rv0678 mutations [16] , the observed mutations in pepQ produced small increases (up to 4-fold) in MICs for both drugs and significantly [45] . The atpE mutations were identified in only 30% of mutants in a large study [15] .
Rv0678 [16, 18] Regulating the expression of the MmpS5-MmpL5 efflux pump 2-to 8-fold increase in Bdq MIC and 2-to 4-fold increase in clofazimine MIC Mutations in Rv0678 have been isolated in vitro upon exposure to clofazimine [18] or Bdq [16] and observed in some postbaseline isolates of Bdq-treated patients [23] . Mutations in Rv0678 were observed in 6.6% [30] and 6.3% [16] of the MDR-TB isolates. They were associated with Bdq MICs exceeding the breakpoint in only 1 of 3 cases (8 of 23) [30] .
pepQ [24] Unclear 4-fold increase in Bdq and clofazimine MICs
Mutations in pepQ have been isolated from mice treated with Bdq. The pepQ mutations were associated with low-level resistance to Bdq and cross-resistance to clofazimine. These mutations reduced the efficacy of both drugs in vivo but did not lead to complete resistance to these drugs [24] .
Abbreviations: ATP, adenosine triphosphate; Bdq, bedaquiline; MDR-TB, multidrug-resistant tuberculosis; MIC, minimum inhibitory concentration.
reduced the effect of these drugs. However, the pepQ mutations did not lead to complete bedaquiline and clofazimine resistance; increasing the bedaquiline dose and the combination of these 2 drugs was associated with a greater anti-TB effect [24] . It has been shown that the combination of bedaquiline and clofazimine has additive bactericidal and sterilizing effects [26] , so even though there is cross-resistance, their combination may be advantageous [24] ; however, they should be combined only if additional antibiotics, which are not substrates of the same efflux pumps, are used to protect them from emergence of resistance. Several combinations of bedaquiline with new drugs have been studied [27] . The potential of various combinations of bedaquiline, clofazimine, pretonamid, sutezolid, and rifapentine was evaluated in mice. Three-and 4-drug combinations including bedaquiline, pretonamid, and sutezolid with or without clofazimine showed better sterilizing activities than the standard first-line regimen in a murine model [26] . Moreover, verapamil was shown to protect bedaquiline monotherapy from resistance in infected mice; its adjunctive use could help preserve bedaquiline activity [28] . During bedaquiline therapy in mice, Rv0678 mutations appear to be selected preferentially over atpE mutations probably because they strike the right balance between reduced bedaquiline susceptibility and the maintenance of fitness [24] . The clinical importance of pepQ function in M. tuberculosis, and how loss of its function might lead to a reduction of susceptibility to bedaquiline and clofazimine, remains unclear. Surveillance is needed to further determine any preexisting diversity in both Rv0678 and pepQ genes and to evaluate any correlation of these mutations with MICs and clinical outcomes in patients receiving 1 or both drugs [24] .
Emergence of Bedaquiline Resistance
In 2005, Andries et al [4] . isolated mutants in vitro and reported the frequency of resistant mutations to bedaquiline as 5 × 10 -7 at 4 times the MIC, and 5 × 10 -8 at 8 times the MIC. The in vitro resistant mutations identified were all within the atpE gene [4] . A second study on 97 independent laboratory-generated bedaquiline-resistant mutants selected from 7 clinical isolates confirmed that the apparent rate of mutations associated with high-level bedaquiline resistance reduces with an increase in the drug concentration [15] . The mutation rate ranged from 4.7 × 10 -7 to 8.9 × 10 -9
, and from 3.9 × 10 -8 to 2.4 × 10 -9 mutations per cell per division at 0.3 mg/L (10 × MIC of bedaquiline-susceptible M. tuberculosis) and at 1.0 mg/L (30 × MIC), respectively. In vitro, no measurable decrease in the fitness of the mutants compared to that of the isogenic wild type was identified. These results suggested that bedaquiline resistance develops at a similar rate to that observed for rifampicin without causing any loss in fitness [15] . The bedaquiline MICs of the mutants ranged from 0.12 mg/L to 3.84 mg/L, which represents 4-to 128-fold increases in the MICs, for the mutants identified [15] .
Bedaquiline resistance has also been documented in clinical studies. In study C208, paired M. tuberculosis (baseline and postbaseline) isolates were isolated from 28 patients, and 13 had a 4-fold increase in bedaquiline MICs [1] . Ten of these 13 patients had isolates with matching genotypes between baseline and postbaseline, and 9 of these had treatment failure or relapse. In a phase 2b clinical trial on 160 patients with newly diagnosed MDR-TB [8] , faster culture conversion was observed in the group treated with bedaquiline in combination with a background regimen compared with the control group. Though only 10 paired isolates were studied, isolates from 1 patient who received bedaquiline and had pre-XDR at baseline showed a 4-fold increase in the bedaquiline MIC at the end of the study compared with baseline. In the C209 study [23] , among 24 patients who had DST for bedaquiline repeated at week 24 or later, 12 had a >4-fold increase in bedaquiline MIC associated with Rv0678 mutations. No mutation in the ATP synthase operon was found [8, 23] .
The compassionate use of bedaquiline in patients with XDR-TB and pre-XDR-TB suggested bedaquiline resistance and cross-resistance with clofazimine [20] [21] [22] . Indeed, in 1 MDR-TB case, bedaquiline resistance was identified due to a mutation in a gene related to an efflux pump that had previously been associated with clofazimine resistance [20] . Recently, Hoffman et al [22] described a patient with MDR-TB resistant to both bedaquiline and clofazimine, who rapidly developed resistance to delamanid. Another study showed that 6.3% of MDR-TB patients without prior clofazimine or bedaquiline exposure had isolates with Rv0678 mutations associated with both bedaquiline and clofazimine resistance [29, 30] . No cross-resistance has been observed between bedaquiline and rifampicin, isoniazid, pyrazinamide, streptomycin, ethambutol, amikacin, or moxifloxacin [1] .
Furthermore, the occurrence of high baseline bedaquiline MIC in 1.9%-2.3% of isolates tested without prior exposure to bedaquiline or clofazimine is worrisome, and more surveillance studies are needed [30] . Whether this preexisting resistance is due to the selection of bedaquiline resistance by historic clofazimine exposure, selection by other compounds that promote bedaquiline resistance through Rv0678 mutations [9] , or preexisting genetic variability is unknown.
Recommendations to Prevent Bedaquiline Resistance
It is suggested bedaquiline be used for 24 weeks in adult patients with pulmonary MDR-TB when an effective treatment regimen cannot otherwise be provided [1] . Bedaquiline is already used to treat MDR-TB and tremendous progress has been made in strengthening laboratory diagnostics, but the TB community is still struggling to build up laboratory networks with the needed capacity for routine culture and DST [10, 25] . DST provides key information for optimizing MDR-TB treatment. Based on laboratory observations on preclinical isolates and limited numbers of clinical isolates, no isolate was found with a MIC >0.5 μg/mL of bedaquiline; therefore, the agar breakpoint was set at ≤0.5 μg/mL. Using the REMA, only 1 isolate had an MIC >0.25 μg/mL, resulting in a REMA breakpoint of ≤0.25 μg/mL [31] [32] [33] . Recently, the cutoff value of ≤0.25 μg/mL was approved by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) as a breakpoint for the use of bedaquiline [34] . It was agreed that the data were insufficient to permit recommendations for susceptibility criteria in the package insert, pending additional information from the confirmatory phase III trial [35] . To determine bedaquiline MIC quality control (QC) ranges for phenotypic DST, a multicountry and multilaboratory study has been recently conducted [36] . Bedaquiline MIC QC ranges for the H37Rv strain were established: 0.015-0.12 μg/mL for 7H10 and 7H11 agar dilution MICs, and 0.015-0.06 μg/mL for the 7H9 broth microdilution MIC. The established DST methodologies and QC ranges will be submitted to the Clinical and Laboratory Standards Institute and EUCAST to provide guidance for DST in laboratories worldwide [36] .
As establishing clinical breakpoints for anti-TB drugs is notoriously difficult due to the absence of clinical outcome data, clinical breakpoints are mainly based on the epidemiological cut-off. For bedaquiline, this problem is even more complex as non-ATP synthase operon mutations are associated with only small changes in MIC in vitro, and in most cases no measurable effect on treatment response has been reported. It is difficult to know how to use molecular tools for detection of drug resistance, especially as mutations in Rv0678 were associated with bedaquiline MICs exceeding the drug sensitivity breakpoint in only 1 of 3 cases (8 of a total 23 studied cases) [30] and had no clear link with treatment outcome [23] . However, resistance mutations resulting in only a moderate increase in MIC that are difficult to detect by MIC testing may be more important than is currently recognized [37] . The increasing use of WGS and collection of clinical outcome/response to therapy in the coming years will undoubtedly help resolve this problem.
WHO strongly urged the development of accurate and reproducible DST for bedaquiline and recommended that in the absence of a specific DST, bedaquiline resistance should be monitored through MIC assessment [32] and resistance development should be evaluated (including repeated DST, if indicated) in patients with treatment failure or relapse. The microbiological monitoring of bedaquiline use is recommended before bedaquiline initiation to detect any bedaquiline resistance and with monthly and end-of-treatment cultures, even after conversion to negative culture. Moreover, early detection of resistance genes is crucial for preventing the onward transmission of resistance. A more complete understanding of the bedaquiline resistance-associated mutations will improve MIC/ bedaquiline-resistance prediction from sequence data, the development of targeted molecular assays, as well as the more accurate interpretation of WGS profiles from clinical isolates. At this moment it remains unclear if the identification of Rv0678 mutations should preclude the use of bedaquiline, and it is too early to assume resistance-associated mutations are confined to the atpE and pepQ genes.
Given that bedaquiline's terminal half-life is extremely long (4-5 months), acquired resistance to the drug might occur when it is the only efficacious anti-TB drug in circulation after therapy stops. The premature discontinuation of treatment may create a high risk of selecting bedaquiline resistance, as low bedaquiline concentrations will persist after other drugs have been eliminated [16] . Thus, bedaquiline discontinuation 4-5 months before scheduled termination of companion medications in the treatment regimen should be considered to reduce or avoid extended exposure to low levels of bedaquiline as a single drug [1] . Subtherapeutic drug levels have been shown to produce tolerance in actively growing TB cultures [38] . Adequate detection of these low levels can be performed using sensitive assays [39] .
Bedaquiline should be administered in a combination regimen with at least 3 additional drugs to which the patient's isolate has been shown to be susceptible in vitro, or 4 drugs to which the patient's isolate is likely susceptible if in vitro testing results are not available. Like any drug, it should not be added as the sole drug to inefficacious companion agents or to a failing regimen [32] . Various combination therapies with new and existing drugs should be the focus of future studies that give consideration to the potential benefits of overcoming existing resistance and preventing the emergence of resistance. Moreover, bedaquiline activity is concentration dependent [4] ; thus, it is important to reach target concentrations. The optimal bedaquiline concentration has not been identified in humans. Patients receiving bedaquiline with a background regimen had an average steady state plasma concentration of 0.6 mg/L [6] . Pharmacokinetic/pharmacodynamic modeling would help predict efficacy and reduce resistance [40] . Therapeutic drug monitoring (TDM) to optimize treatment may also be helpful [41] . Nevertheless, routine TDM is challenging due to the need for specialized laboratories capable of processing the samples. Although, as drug concentrations can now be measured from dried blood spots, the storage and shipment problems associated with TDM and associated costs are reducing [42] .
As explained above, treatment nonadherence in bedaquiline-containing regimens will likely result in bedaquiline monotherapy due to long bedaquiline half-life compared to other drugs. This could lead to treatment failure, relapse, or acquired resistance. Furthermore, bedaquiline should be concomitantly taken with food since this coadministration increases the drug exposure. In a mouse model, verapamil was shown to enhance the bedaquiline activity; thus, daily dose of bedaquiline can be reduced with coadministration of verapamil and its dose-related toxicities can be decreased. In addition, the verapamil use at week 1 seems to potentiate early bactericidal activity for bedaquiline. This synergistic effect needs to be confirmed in humans [28] .
The combination of bedaquiline with CYP3A4 inducers or inhibitors requires extreme caution. However, patients with TB/human immunodeficiency virus (HIV) coinfection require antiretroviral therapy during TB treatment. Lopinavir/ ritonavir, a potent inhibitor of CYP3A4, significantly increased plasma bedaquiline concentrations and its N-monodesmethyl metabolite (M2); bedaquiline toxicities may be enhanced [43] . The clinical implications of this interaction remain unclear. If bedaquiline is administered with these medications, plasma drug concentrations should be monitored to ensure proper drug therapy and minimize the risk of acquisition of drug resistance [1] . Rifampicin and rifapentine, strong inducers of CYP3A4, reduced substantially both bedaquiline and M2 concentrations; concomitant use of bedaquiline with these drugs is not recommended, even with dose adjustment [44] .
CONCLUSIONS
The threat of bedaquiline resistance and cross-resistance with clofazimine emphasizes the crucial need for systematic surveillance. The development and standardization of DST methodology to new anti-TB compounds are urgently needed to monitor the emergence of resistance and should be a higher priority when new drugs are introduced [20] . For new agents such as bedaquiline, understanding any target and non-targetbased mechanisms is essential to minimize the development of resistance. Such information will help to develop appropriate DST for bedaquiline, manage treatment failure and relapse, and setup a surveillance program for drug susceptibility. 
